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Cellular/Molecular

The Major Brain Cholesterol Metabolite
24(S)-Hydroxycholesterol Is a Potent Allosteric
Modulator of N-Methyl-D-Aspartate Receptors
Steven M. Paul,1,2 James J. Doherty,1 Albert J. Robichaud,1 Gabriel M. Belfort,1 Brian Y. Chow,1 Rebecca S. Hammond,1
Devon C. Crawford,3 Andrew J. Linsenbardt,3 Hong-Jin Shu,3 Yukitoshi Izumi,3 Steven J. Mennerick,3
and Charles F. Zorumski3
1

Sage Therapeutics, Cambridge, Massachusetts 02142, 2Appel Alzheimer’s Disease Research Institute, Brain and Mind Research Institute, Departments of
Psychiatry and Pharmacology, Weill Cornell Medical College, New York, New York 10065, and 3Department of Psychiatry and Taylor Family Institute for
Innovative Psychiatric Research, Washington University School of Medicine, St Louis, Missouri 63110

N-methyl-D-aspartate receptors (NMDARs) are glutamate-gated ion channels that are critical to the regulation of excitatory synaptic
function in the CNS. NMDARs govern experience-dependent synaptic plasticity and have been implicated in the pathophysiology of
various neuropsychiatric disorders including the cognitive deficits of schizophrenia and certain forms of autism. Certain neurosteroids
modulate NMDARs experimentally but their low potency, poor selectivity, and very low brain concentrations make them poor candidates
as endogenous ligands or therapeutic agents. Here we show that the major brain-derived cholesterol metabolite 24(S)-hydroxycholesterol
(24(S)-HC) is a very potent, direct, and selective positive allosteric modulator of NMDARs with a mechanism that does not overlap that of
other allosteric modulators. At submicromolar concentrations 24(S)-HC potentiates NMDAR-mediated EPSCs in rat hippocampal neurons but fails to affect AMPAR or GABAA receptors (GABAARs)-mediated responses. Cholesterol itself and other naturally occurring
oxysterols present in brain do not modulate NMDARs at concentrations ⱕ10 M. In hippocampal slices, 24(S)-HC enhances the ability of
subthreshold stimuli to induce long-term potentiation (LTP). 24(S)-HC also reverses hippocampal LTP deficits induced by the NMDAR
channel blocker ketamine. Finally, we show that synthetic drug-like derivatives of 24(S)-HC, which potently enhance NMDAR-mediated
EPSCs and LTP, restore behavioral and cognitive deficits in rodents treated with NMDAR channel blockers. Thus, 24(S)-HC may function
as an endogenous modulator of NMDARs acting at a novel oxysterol modulatory site that also represents a target for therapeutic drug
development.

Introduction
N-methyl-D-aspartate receptors (NMDARs) are heterotetrameric ligand-gated ion channels implicated in forms of synaptic
plasticity, such as long-term potentiation (LTP) and long-term
depression (LTD), thought to underlie learning and memory
(Bashir et al., 1991; Asztely et al., 1992; Cui et al., 2004; Traynelis
et al., 2010). NMDARs have been implicated in the pathophysiReceived May 31, 2013; revised Sept. 6, 2013; accepted Sept. 23, 2013.
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ology of several neuropsychiatric disorders including schizophrenia, depression, Alzheimer’s disease, and epilepsy (Li and Tsien,
2009; Zorumski and Izumi, 2012) and many of these disorders
are associated with deficits in cognitive function. Because
NMDAR channel blockers, such as ketamine and phencyclidine
(PCP) produce psychotic symptoms and cognitive deficits (Luby
et al., 1959) mimicking schizophrenia in humans (for review, see
Tamminga, 1998; Coyle, 2006), there has been considerable interest in discovering drugs that augment NMDAR function to
treat the debilitating negative and cognitive symptoms of schizophrenia (Tamminga, 1998; Coyle, 2006). Recent clinical studies
of NMDAR enhancers appear to support this strategy (Coyle,
2006).
NMDARs are regulated by various natural substances including neuroactive steroids (Williams, 2009). Neuroactive steroids
are natural or synthetic steroids that directly and rapidly modulate ligand-gated ion channels, such as GABAA-type receptors
(GABAARs) or NMDARs to alter inhibitory and excitatory neurotransmission (Majewska et al., 1986; Paul and Purdy, 1992).
Among these, the neurosteroid pregnenolone sulfate (PREGS)
has been studied as a potential endogenous NMDAR modulator
(Belelli and Lambert, 2005). PREGS is a positive and negative
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Figure 1. 24(S)-HC and SGE-201 are potent oxysterol positive allosteric modulators of NMDA receptors. A, Natta projection structures for 24(S)-HC, SGE-201, and SGE-301. Note that the key
hydroxyl group (denoted in red) in all three structures is on the same carbon relative to the cholesterol backbone. The similarity in the location of the hydroxyl group is further emphasized in the three
dimensional stick and ball models below (D-ring and C-17 side chain shown). The 3-␣ methyl group that distinguishes SGE-201 and SGE-301 is circled in red. B, Effects of endogenous oxysterols and
other cholesterol metabolites on NMDA receptor currents. Cultured primary hippocampal neurons were preincubated with 10 M test compound in 0.5 M glycine for 90 s, followed by 10 s NMDA
(10 M). The percentage change in NMDA current is plotted. C, Representative traces from B. The red lines represent application of test article (note that the red lines do not encompass the full 90 s
of preincubation). The black lines represent the application of NMDA (10 M, 10 s). Scale bar: vertical ⫽ 200 pA, horizontal ⫽ 10 s. D, Active oxysterols compared with pregnenolone metabolites.
All compounds were tested at 10 M, 90 s preincubation, with the exception of 24(S)-HC (10 M, 360 s preincubation), and pregnenolone sulfate (10 and 50 M, 90 s preincubation). Cholesterol was
solubilized in ethanol rather than DMSO. Asterisk represents a significant difference from current induced by NMDA alone ( p ⬍ 0.05).

allosteric modulator of NMDARs and GABA-ARs, respectively
(Wu et al., 1991; Park-Chung et al., 1999; Horak et al., 2004).
PREGS enhances LTP in hippocampal slices (Sliwinski et al.,
2004), enhances memory, and reverses memory impairment induced by NMDAR blockers in rodents (Flood et al., 1992; Mathis
et al., 1994). However, PREGS is a relatively weak NMDAR modulator in vitro (Wu et al., 1991) and is essentially undetectable in
rodent brain (Liere et al., 2009). Nonetheless, these findings have
prompted efforts to find other steroidal NMDAR modulators.
In a preliminary report, Madau et al. (2009) identified other
steroid-like NMDAR-positive allosteric modulators (PAMs).
The oxysterol derivative [⌬ 5,6-3␤-oxy-nor-cholenyl]-dimethylcarbinol (CAS No. 35882-85-0; SGE-201) and several structurally
related oxysterol derivatives appeared to act as potent NMDAR
PAMs in vitro (Madau et al., 2009) and in vivo (Connick et al.,
2009), but the exact nature of this PAM activity and it relationship to activity observed for PREGS remain unclear. Given the
structural similarity of these compounds to natural oxysterols
and the recently appreciated role oxysterols play in cell signaling
(Janowski et al., 1996; Corcoran and Scott, 2006), we screened a
series of natural oxysterols and related compounds at NMDARs
and now report that the major cholesterol metabolite in brain,
24(S)-hydroxycholesterol (24(S)-HC), is a highly selective and
potent NMDAR PAM. We show that 24(S)-HC interacts with a

privileged NMDAR binding site that is distinct from PREGS. We
also identify synthetic derivatives of 24(S)-HC that selectively
and potently modulate NMDAR function. These data suggest
that 24(S)-HC may serve as a natural modulator of NMDARs,
acting at a novel oxysterol regulatory site that is a potential target
for therapeutic drug development.

Materials and Methods
Chemicals and solutions
Oxysterols were prepared as concentrated stocks in 100% DMSO; working solutions contained ⱕ0.1% DMSO. SGE-201 (Madau et al., 2009),
previously described as an intermediate in the synthesis of steroids, was
synthesized as described previously (Plattner and Pataki, 1943; Mouriño
et al., 1978). Briefly, SGE-201 was prepared in four steps from commercially available 3␣, 6␣-dihydroxy-5␤-cholan-24-oic acid. First, the
methyl ester was formed, followed by tosylation of the 3␣- and 6␣hydroxyl groups. In a single pot under mild basic conditions, the C5/C6
double was formed after elimination of the 6-tosylate and the 3␤hydroxyl moiety was obtained after inversion of the configuration of the
3␣-tosylate upon hydrolysis. In the last step, the dimethyl groups were
installed at C-24 via methyl lithium addition to the ester. SGE-301 was
synthesized from SGE-201 in a straightforward manner. Dess–Martin
oxidation of the 3␤-hydroxy to the ketone, followed by methyl Grignard
addition yielded SGE-301 in two steps. SGE-201 and SGE-301 were characterized by liquid chromatography (LC)/MS and 1H-NMR as described
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in patent: WO2013/036835A1 and were ⱖ95% pure. 24(S)-HC and all
other steroid derivatives were purchased from Avanti Polar Lipids or
Steraloids.

Whole-cell recording
Hippocampal cultures were prepared using previously reported methods
(Mennerick et al., 1995). Whole-cell and excised-patch recordings were
made using an Axopatch 200B amplifier (Molecular Devices) at room
temperature from primary dissociated cultures of mouse (see Fig. 1) or
rat (see Figs. 2–5, 7) hippocampal neurons from either sex (days in vitro
5–13) grown as mass cultures or on substrate microdots to elicit recurrent EPSC/IPSCs (Mennerick et al., 1995). Bath solutions for the screening studies in Figure 1 contained the following (in mM): 140 NaCl, 3 CsCl,
0.2 CaCl2, 10 glucose, 10 HEPES, 4.5 sucrose, 0.0005 glycine, 0.00035
TTX, pH 7.4. Bath solution for subsequent studies in cultured neurons
contained the following (in mM): 140 NaCl, 4 KCl, CaCl2 (1 for synaptic
studies, 0.5 for exogenous NMDA applications), 10 glucose, 10 HEPES,
pH 7.25. NBQX (1 M), D-APV (25 M), and gabazine (10 M) were
included as needed to isolate relevant currents. Membrane potential was
typically clamped to ⫺70 mV, and saline solution contained 0.5 M
glycine and was nominally Mg 2⫹-free. Whole-cell pipette solutions for
the screening studies in Figure 1 contained the following (in mM): 120
CsCl, 2 ATP, 0.2 CaCl2, 10 EGTA, 10 HEPES, 1 MgCl2, 20 TEA-Cl, 0.2
cAMP, pH 7.2. For subsequent studies in cultured neurons the whole-cell
pipette solution contained the following (in mM): 140 cesium methanesulfonate, 4 NaCl, 0.5 CaCl2, 5 EGTA, 10 HEPES, pH 7.3, and the same
solution was used for excised outside-out patch recordings. For evoked
recurrent PSCs, potassium gluconate replaced cesium methanesulfonate.
For application of drugs to whole cells and to excised patches, a multibarrel solution exchange system with common delivery tip was used
(Warner Instruments). The common tip was placed 0.5 mm from the
center of the microscope field. Solution exchange times were 120 ⫾ 14 ms
(10 –90% rise) estimated from the rise of junction currents at the tip of an
open patch pipette. Experiments were performed at room temperature,
and quantification of whole-cell peak current response was used for all
figure summaries.
Outside-out membrane patches were excised from DIV2-5 hippocampal neurons. Currents were sampled at 8 kHz and filtered at 1 kHz. NPo
values were calculated by idealization of traces using QUB software (University of Buffalo). Perfusion buffer for patch experiments included 1 M
NBQX, 0.5 M tetrodotoxin, and 10 M gabazine.
Electrophysiological recordings obtained from heterologous cells expressing NMDA receptors were obtained as follows. HEK 293 cells stably
expressing human GluN1 (transcript variant NR1-3, RefSeq: NM_
007327.1, NP_015566) were transiently transfected with a plasmid
encoding human GluN2A (RefSeq: NM_000833.2, NP_000824). In subsequent experiments (see Fig. 6C) constructs used for transient HEK cell
transfections included rat GluN1A splice variant (accession numbers
U11418, U08261), mouse GluN2A (NM008170), rat GluN2B (M91562),
rat GluN2C (M91563), and rat GluN2D (L31611). Constructs were validated by selective restriction digests and functional testing, including
verification of high Zn 2⫹ sensitivity of GluN2A vs. GluN2B subunits and
low Mg 2⫹ sensitivity of GluN2C and GluN2D subunits. Manual patchclamp electrophysiology recordings were obtained with an EPC-7/EPC10, HEKA Electronics Amplifier. Electrical signals were captured and
analyzed with PatchMaster Software (HEKA Electronics). Each compound was tested at 0.1 M or 1.0 M in the presence of NMDA (30 M)
and glycine (5.0 M). NMDA and glycine induced currents in the presence of test compound were compared with current induced by NMDA
and glycine alone. Fifty micrometers PREGS served as the positive control. 0.1% DMSO was used as the vehicle.

NaHCO3, 10 glucose, bubbled with 95% O2/5% CO2 at 4 – 6°C.
Acutely prepared slices were placed on mesh in 10 ml beakers containing gassed ACSF and maintained for at least 1 h at 30°C before
experiments (Tokuda et al., 2010).
At the time of study, slices were transferred individually to a submerged recording chamber. Experiments were performed at 30°C with
continuous bath perfusion of ACSF at 2 ml/min. Extracellular recordings
were obtained from the apical dendritic layer of the CA1 region (stratum
radiatum) for analysis of population EPSPs. EPSPs were measured by
their maximal slopes and were monitored by applying single stimuli to
the Schaffer collateral pathway every 60 s at half-maximal intensity (estimated from baseline input-output curves). After establishing stable
responses for at least 10 min, LTP was induced using a standard 100 Hz ⫻
1 s high-frequency stimulus (HFS). This HFS produces reliable LTP at
P30, but is subthreshold for LTP at P120 resulting only in short-term
potentiation (STP) under the ionic conditions used (Izumi and Zorumski, 1999). The magnitude of LTP was determined 60 min following HFS.
Signals were digitized and analyzed using PCLAMP software (Molecular
Devices).
Slice data are expressed as percentage of baseline control responses (set
at 100%). In these studies, n represents the number of slices studied in a
given condition, and, unless stated otherwise, data were normalized with
respect to initial control responses. Points in the graphs without error
bars have SEM smaller than the symbol size. Statistical comparisons are
based on analysis of input/output curves at baseline and 60 min following
HFS, and represent the degree of change at the half-maximal point on the
input/output curves compared with baseline responses. Slice statistical
analyses were performed using commercial software (SigmaStat 3.11;
Systat Software). For slice studies, if a test of equal variance failed, the
nonparametric Mann–Whitney rank sum test was applied.

Hippocampal slice recordings

Bioanalytical methods

Hippocampal slices were prepared from juvenile [postnatal day
(P)30 –32] or adult (P120) Sprague Dawley rats purchased from Harlan (Izumi and Zorumski, 1999). Rats were anesthetized with isoflurane and decapitated. Slices were cut transversely into 500 m slices
using a rotary slicer in artificial CSF (ACSF) containing the following
(in mM): 124 NaCl, 5 KCl, 2 MgSO4, 2CaCl2, 1.25 NaH2PO4, 22

Plasma and brain concentrations of SGE-201 and SGE-301 were determined by LC-MS/MS. Briefly, brain samples were homogenized with 3
volumes (v/w) of PBS, pH 7.4, before analysis. One-hundred milliliters
internal standard (diclofenac 200 ng/ml) was added to aliquots of plasma
(30 l) or brain (200 l) and extracted with 1 ml of methyl tert-butyl
ether. The extracts were centrifuged and a portion of the organic phase

Figure 2. 24(S)-HC and SGE-201 are effective at submicromolar concentrations. A, Potentiation of 10 M NMDA (0.5 M glycine) by increasing 24(S)-HC concentrations with 40 s oxysterol preapplication in a DIV5 rat hippocampal neuron. B, Potentiation values for 24(S)-HC and
for SGE-201 were fit with the Hill equation (solid lines). EC50 estimates were 0.11 M for SGE201 (N ⫽ 7 cells), and 1.2 M for 24(S)-HC (N ⫽ 5 cells).
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reported as the mean ⫾ SEM and data were
analyzed using one-way ANOVA with Bonferroni post hoc comparisons.
Subchronic PCP model of schizophrenia. Male
Long–Evans rats (160 –220 g, N ⫽ 12–15 per
treatment group) were group housed in a climate controlled environment (22 ⫾ 2°C, 12 h
light/dark cycle) with ad libitum access to food
and water. PCP (5 mg/kg; Sigma-Aldrich) or
vehicle (0.9% saline) was administered twice
daily for 7 d (intraperitoneally) followed by a
7 d washout period (Grayson et al., 2007;
Snigdha and Neill, 2008). On day 13, rats were
habituated to the test chamber (90 ⫻ 90 ⫻ 40
cm square arena; 60 lux) for 10 min. On day 14,
rats received acute intraperitoneal administration of SGE-301 (3, 10, or 30 mg/kg) or vehicle
(30% Captisol⫹ 0.01% Tween 80) 60 min before testing social interaction, or risperidone as
a positive control (0.2 mg/kg, i.p.; 60 min pretreatment). Social interaction (SI) was tested
during the light phase by placing each rat into
the test chamber with an unfamiliar naive male
rat (Snigdha and Neill, 2008). Spontaneous SI
was monitored by an observer blind to treatment for 10 min. The time spent engaged in
active nonaggressive social behavior (defined
as sniffing, following, grooming, kicking,
mounting, wrestling, boxing or crawling over/
under) was recorded. After SI testing, rats received an additional 7 d washout period before
Figure 3. Slow oxysterol reversibility. A, B, NMDA (10 M) currents were potentiated with 24(S)-HC (2 M) or with SGE-201 novel object recognition (NOR) testing. On
(0.2 M, red traces) with repeated 20 s preapplication of potentiator between successive NMDA challenges. Following 60 s total day 20 the rats were habituated to the NOR
oxysterol exposure (three red traces), cells were challenged with saline wash for 80 s (four black traces). There was little reversibility chamber (60 ⫻ 60 ⫻ 40 cm; 60 lux) for 10 min
for either drug. Cells were then challenged with ␥-cyclodextrin (CDX; 500 M) wash, before NMDA application in the absence of (Grayson et al., 2007). On day 21, rats received
␥-cyclodextrin (blue traces). A1, B1, Traces show results from representative neurons. A2, B2, Summary plots for five and acute intraperitoneal administration of SGEsix cells, respectively. ␥-Cyclodextrin extracted SGE-201 potentiation but not 24(S) potentiation. C, D, Oxysterols were premixed 301 (1, 3, or 10 mg/kg), vehicle (30% Captiwith ␥-CDX in solution at subsaturating oxysterol concentrations (0.5 M for each compound mixed with 1 mM ␥-cyclodextrin). sol⫹ 0.01% Tween 80) or risperidone as a
␥-Cyclodextrin effectively reduced the free concentration of SGE-201, indicated by reduced potentiation, but failed to affect positive control (0.2 mg/kg, i.p.) 60 min before
NOR training, where each rat is allowed a max24(S)-HC potentiation.
imum of 6 min to accumulate 8 s of exploration
on each of two identical objects (familiar obwas removed and evaporated to dryness under nitrogen. The extracts
jects). After a 30 min retention interval, rats were placed back into the
were reconstituted in 60 l of methanol/water for analysis. A 20 l aliarena with one familiar and one novel object and the duration of object
quot was chromatographed on a Waters Atlantis C18 column eluting
exploration was scored manually by an observer blind to treatment for 3
with a gradient of methanol/water/0.2% formic acid. SGE-201 was demin. For NOR, the discrimination ratio was calculated by dividing the
tected using positive ion electrospray ionization and mass transitions of
time spent exploring the novel object by the total object exploration time
371.3/353.3 on a Sciex API 4000 Q-Trap. The limit of quantitation was
in the test session. This measure corrects for variance in total exploration.
typically 1 ng/ml for plasma and 4 ng/g for brain. SGE-301 was quantiWith this ratio, 0.5 ⫽ chance performance (equal exploration of novel
tated following the same tissue extraction procedure. The reconstituted
and familiar objects); 1⫽ only novel object exploration, and 0 ⫽ only
samples were chromatographed on a Waters Acquity BEH C18 column
familiar object exploration. All behavioral data are reported as the
with a methanol/ water/0.2% formic acid solvent gradient. SGE-301 was
mean ⫾ SEM and were analyzed with ANOVA and Bonferroni post hoc
detected using positive ion electrospray ionization with mass transitions
comparisons.
of 385.3/95.0. The limit of quantitation was typically 2 ng/ml for plasma
and 40 ng/g for brain.
Results

Behavioral methods
MK-801 impaired Y-maze spontaneous alternation task. Male Swiss CD-1
mice (7– 8 weeks, N ⫽ 17–19 per treatment group) were used to assess
spontaneous alternation behavior in the Y-maze test (Hefco et al., 2003).
The maze was constructed from clear Plexiglas with arms at 120° angles
and with dimensions in cm: 57 long, 17 wide, and 35 high. Each mouse
was placed in the center of the maze at the start of the study and allowed
to move freely for 10 min. An alternation is defined as sequentially entering all three arms without reentry into a previously visited arm. Percentage alternation was calculated as follows: (alternations/total
entries ⫺ 2) ⫻ 100. One hour before testing mice received an intraperitoneal injection of vehicle (25% hydroxypropyl-␤-cyclodextrin in PBS)
or SGE-201 (3, 10, and 30 mg/kg) in a volume of 10 ml/kg. MK-801 was
administered 30 min before testing (0.25 mg/kg in water, i.p.). Data are

24(S)-Hydroxycholesterol is a potent NMDAR modulator
To determine whether endogenous oxysterols modulate
NMDARs, we initially screened a series of naturally occurring
oxysterols (and structurally related sterols and steroids; Fig.
1 A, B) at 10 M in neonatal mouse hippocampal neurons using
whole-cell patch-clamp electrophysiology (Fig. 1B, C). Comparators were SGE-201 (10 M) and PREGS (50 M) (Fig. 1D).
Remarkably, 24(S)-HC, one of the most abundant endogenous cholesterol metabolites in brain, significantly potentiated NMDAR-mediated currents (Fig. 1B, C). 24(S)-HC did not
alter membrane current on its own in the absence of NMDA.
None of the other oxysterol liver X receptor (LXR) ligands, including 22(R)-HC and 20(S)-HC, affected NMDARs at concen-

17294 • J. Neurosci., October 30, 2013 • 33(44):17290 –17300

Paul et al. • A Cholesterol Metabolite with NMDA Receptor Modulatory Activity

Figure 4. Occlusion studies suggest a unique mechanism for oxysterols versus other lipophilic positive modulators. A, B, Examples of occlusion protocol. Cells were preincubated for ⬎5
min in 10 M 24(S)-HC then challenged with 10 M NMDA plus 50 M PREGS (A) as a representative nonoccluding potentiator or 0.2 M SGE-201 (B) as a representative occluding potentiator. C, Summary of results from 6 to 10 cells per bar for the four indicated modulators.
Arachidonic acid was used at 5 M. SGE-301 was used at 0.5 M. Asterisks indicate a significant
reduction in potentiation ( p ⬍ 0.05).

Figure 6. Potentiation of recombinant receptors suggests little or no subunit selectivity. A,
HEK-293 cells stably expressing human GluN1–3 and transiently expressing human GluN2A
were activated with NMDA (30 M) and glycine (5.0 M) (small gray bars). After determining
the baseline response to NMDA and glycine, a test compound (as indicated) was added at 0.1
M (short white bars) or 1 M (tall white bars). B, The mean (⫾ SEM) percentage potentiation
(by 1 M test compound) above NMDA and glycine alone is plotted. Asterisks denote a significant difference from baseline ( p ⬍ 0.05). C, Sample traces from HEK cells transiently transfected with GluN1a plus each of the indicated GluN2 subunits. Potentiation of 10 M NMDA
currents (0.5 M glycine) by 0.2 M SGE-201 is shown (gray traces of each pair). D, Each subunit
combination exhibited significant potentiation by SGE-201 above baseline (asterisks), but no
significant difference in potentiation values among subunits was detected.
Figure 5. Potentiation in excised outside-out membrane patches. A, Baseline NMDAR channel activity (black trace) in 300 M NMDA in an excised outside-out patch from a DIV2 hippocampal neuron was augmented following SGE-201 incubation for 60 s (0.2 M, red trace).
The patch was excised before drug applications. B, The all-points histograms represent 30 s of
NMDA-induced channel activity before (black) and following (red) SGE-201 application from
the patch represented in A. C, Summary of NPo analysis from eight excised outside-out patches.

trations ⱕ10 M (Fig. 1B–D). Cholesterol itself was also inactive
at concentrations ⱕ10 M (Fig. 1B).
The concentration-response relationship of NMDAR modulation by 24(S)-HC and SGE-201 was explored by preincubating
hippocampal neurons for 40 s in increasing concentrations of
compound before agonist application (Fig. 2). Both oxysterols
potentiated NMDA-induced currents at submicromolar concentrations (Fig. 2 A, B). Interestingly, 24(S)-HC was active at concentrations well below those measured in the CNS (Meljon et al.,
2012). SGE-201 was ⬃5- to 10-fold more potent than 24(S)-HC
(Fig. 2B). We synthesized another synthetic analog, SGE-301,
designed to be more bioavailable than 24(S)-HC or SGE-201 by
introduction of a 3␣-methyl group (Fig. 1A), and evaluated its
activity in subsequent experiments (see below).
Although we did not fully explore the pharmacological mechanisms of oxysterol modulation, an interesting aspect of potentiation is that it did not appear to depend strongly on agonist or
coagonist concentration. Normalized to baseline responses, SGE201 potentiation of responses of hippocampal neurons to a near
saturating concentration of 300 M NMDA was 2.8 ⫾ 0.6 (N ⫽
5). Under comparable conditions, the potentiation of responses

to 10 M NMDA (below the EC50; Patneau and Mayer, 1990) was
2.5 ⫾ 0.8 (N ⫽ 5, p ⬎ 0.05). Similarly, potentiation did not
strongly depend on coagonist concentration. Potentiation of responses to 10 M NMDA in 0.5 M glycine was similar to potentiation in 10 M glycine (2.1 ⫾ 0.2 vs 2.4 ⫾ 0.3, p ⬎ 0.05, N ⫽ 7).
Oxysterols modulate NMDARs with slow kinetics
In pilot experiments we found that 24(S)-HC and SGE-201 required preincubations ⬎20 s to reach maximal effect, and once
established, potentiation was poorly reversible. It is possible that
the slow onset of potentiation and slow reversibility observed for
these ligands could result from a direct receptor interaction that
involves membrane partitioning or cell permeation (Akk et al.,
2005). Alternatively, potentiation could involve indirect modulation by second messengers or transcriptional regulation. Both
of these alternative mechanisms have precedent in explaining the
effects of oxysterols in other signaling pathways (Kalaany and
Mangelsdorf, 2006; Nachtergaele et al., 2012). Furthermore, it
appeared that macroscopic desensitization was augmented in the
presence of oxysterol (Fig. 3A1), a phenomenon that represents
additional kinetic complexity and could reflect a mixed potentiating/inhibiting action similar to PREGS (Horak et al., 2004). If
the slow oxysterol actions require rate-limiting partitioning that
equilibrates with a receptor binding site, potentiation might be
rapidly reversed by applying ␥-cyclodextrin, a scavenger of membrane neurosteroids and sterols (Ohtani et al., 1989; Akk et al.,
2005). We found that ␥-cyclodextrin effectively reversed poten-
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Figure 7. Selective potentiation of NMDAR EPSCs. A, Potentiation by 1 M 24(S)-HC of evoked NMDAR EPSCs isolated with 1 M NBQX and 10 M gabazine. Slow onset, slow reversibility, and
relative ␥-CDX insensitivity paralleled effects on responses to exogenous NMDA. B, Pharmacologically isolated AMPAR EPSCs (10 M gabazine and 25 M D-APV) were unaffected. C, SGE-201 (0.2
M; 90 s) also potentiated peak NMDAR EPSCs with little effect on decay time course of the EPSCs (inset). D, Summary of effects of 1 M 24(S)-HC on NMDAR EPSCs and AMPAR EPSCs (N ⫽ 8 and
7, respectively). AMPARs were statistically unaltered. A summary of 0.2 M SGE-201 effects is also shown (N ⫽ 7 and 6). E, GABAAR IPSCs were statistically unaltered by prolonged 24(S)-HC
application (N ⫽ 11 for1 M 24(S)-HC and N ⫽ 6 for 1 M SGE-201).

tiation of NMDARs by SGE-201 but
much less so for 24(S)-HC (Fig. 3 A, B).
Although this result could suggest distinct
mechanisms of NMDAR potentiation by
SGE-201 and 24(S)-HC, it is also possible
that the natural oxysterol may not as efficiently form inclusion complexes with
␥-cyclodextrin, or may partition at a site
inaccessible to ␥-cyclodextrin.
To test the former possibility, we prepared solutions of 0.5 M 24(s)-HC or 0.5
M SGE-201 with 1 mM ␥-cyclodextrin. If
oxysterols effectively bind ␥-cyclodextrin,
the mixture should result in a lower free
oxysterol concentration, and brief exposures to the mixtures should reduce
potentiation compared with control exposures in the absence of ␥-cyclodextrin.
Consistent with this expectation, SGE201 potentiation was reduced compared
with a control solution containing no
␥-cyclodextrin (Fig. 3C,D). By contrast,
the effect of a subsaturating 24(S)-HC
concentration was unaffected by ␥-cyclodextrin premixing (Fig. 3D). These results are consistent with the idea that
24(S)-HC fails to effectively bind ␥-cyclodextrin, explaining the resistance to cyclodextrin extraction of 24(S)-HC.
Figure 8. Augmentation of LTP by 24(S)-HC. A, P120 hippocampal slices were challenged with a brief HFS that produces STP,
but not LTP (open symbols). However, in the presence of SGE-201 the same stimulus effectively induced LTP (closed symbols).
Responses in control slices were 91.9 ⫾ 5.6% of baseline EPSP slope at 50% of maximum on the I/O curve, 60 min following HFS.
With SGE-201 present, EPSP slopes were increased to 156 ⫾ 10.8% of baseline ( p ⬍ 0.001, N ⫽ 5 slices each). B, Similar
experiment with 24(S)-HC. Black symbols represent effect of 1 M 24(S)-HC (166.1 ⫾ 19.4% of baseline; p ⬍ 0.001), whereas 0.1
M 24(S)-HC did not significantly enhance LTP induction (103.9 ⫾ 9.8% of baseline, p ⫽ n.s., N ⫽ 5 slices each). Insets for A and
B show representative traces. Dashed lines are baseline and solid lines represent traces in the indicated oxysterol 60 min following
HFS. Calibration bars: 1 mV, 5 ms.

24(S)-Hydroxycholesterol shares a
common mechanism of action with
SGE-201 and SGE-301 but not with
known lipophilic positive modulators
To test more directly whether 24(S)-HC
shares a common mechanism of action
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Figure 9. SGE-201 and SGE-301 reverse synaptic plasticity deficits following NMDA receptor blockade. A, B, Reversal of ketamine suppression of long-term potentiation (LTP) by 24(S)-HC (A) and
SGE-201 (B) in P30 hippocampal slices. Open symbols are baseline response following ketamine administration (1 M, 30 min preincubation) to 100 Hz ⫻ 1 s HFS (vertical arrow). The change in
baseline EPSP slope was 93.1 ⫾ 2.3% 60 min following HFS in ketamine-treated control slices. Solid symbols represent the same condition except 0.5 M 24(S)-HC (A; 131.3 ⫾ 6.7% of baseline,
p ⬍ 0.001, N ⫽ 5) or SGE-201 (B; 129.1 ⫾ 9.2% of baseline, p ⬍ 0.001, N ⫽ 5) was present; N ⫽ 5 each, p ⫽ 0.008. Calibration bars: 1 mV, 5 ms.

with synthetic oxysterol analogues and (or) shares a mechanism
with the known lipophilic modulators PREGS or arachidonic
acid, we incubated neurons for ⬎5 min in 10 M 24(S)-HC, and
then challenged cells with agonist plus another modulator to
probe occlusion (Fig. 4). 24(S)-HC preincubation did not significantly occlude PREGS or arachidonic acid potentiation but prevented further SGE-201 potentiation and potentiation by the 3␣methyl analog SGE-301. These latter two results demonstrate a
shared mechanism of action between natural 24(S)-HC and the
synthetic analogues and also demonstrate that preincubation in
10 M 24(S)-HC was saturating, important for the interpretation
of the PREGS and arachidonic acid results. Thus, 24(S)-HC likely
acts via distinct modulatory sites from known modulators, but
24(S)-HC, SGE-201, and SGE-301 likely share a common or
overlapping binding site.
Oxysterols show robust NMDAR PAM activity in excised
membrane patches
Recently PREGS was found to induce NMDAR receptor insertion
into the plasma membrane as part of its mechanism of potentiation
(Kostakis et al., 2013), although PREGS also modulates NMDARs in
excised membrane patches where insertion is unlikely (Bowlby,
1993; Abdrachmanova et al., 2001). To determine whether oxysterol modulation primarily involves receptor insertion, potentially explaining its slow onset and poor reversibility, we
explored the effects of SGE-201 in excised outside-out membrane
patches from hippocampal neurons. In support of direct allosteric modulation, but contrary to expectations for receptor insertion, we found that SGE-201 robustly potentiated NMDAR
channel activity in excised outside-out membrane patches (Fig.
5). All-point histograms revealed that potentiation increased
channel number and (or) open probability but did not discernibly increase single-channel current (Fig. 5B). Evaluation of NPo
values from eight patches showed quantitative increases consistent with potentiation values for whole-cell NMDA currents.
Given that the potentiation in outside-out patches, where receptor insertion is extremely unlikely, is quantitatively similar to
whole-cell potentiation, it appears that 24(S)-HC mainly modulates NMDARs through a mechanism that does not involve receptor insertion or transcription. Although the results do not
completely exclude a membrane-delimited second messenger

mechanism, the data are most consistent with binding to a direct
modulatory site.
Oxysterols modulate recombinant NMDARs
Because native cells are heterogeneous in their NMDAR subunit
combination, we examined oxysterol modulation of recombinant receptors to gain additional insight into selectivity. We first
evaluated 24(S)-HC and the synthetic analogues SGE-201 and
SGE-301 on GluN2A-containing receptors expressed in HEK
cells (Fig. 6 A, B). Each of the three analogues (Fig. 6A; 0.1 and 1
M) significantly potentiated NMDA responses, with the synthetic analogues exhibiting stronger effects than the natural oxysterol (Fig. 6B).
We also used recombinant receptors transiently expressed in
HEK cells to evaluate subunit dependence of oxysterol effects.
PREGS exhibits strong GluN2 subunit selectivity, potentiating
GluN2A and GluN2B responses, and inhibiting responses from
GluN2C and GluN2D-containing NMDARs (Malayev et al.,
2002; Horak et al., 2006). By contrast, we found no qualitative
difference in subunit dependence of oxysterol potentiation. SGE201 significantly potentiated responses from all subunit combinations (Fig. 6C,D), and potentiation values did not differ
significantly among the GluN2 subunits. Thus, these results further distinguish the actions of oxysterols from the known modulator PREGS.
24(S)-Hydroxycholesterol is a selective NMDAR modulator
The selectivity of 24(S)-HC for NMDARs was evaluated by examining evoked EPSCs and IPSCs in cultured hippocampal neurons. 24(S)-HC potentiated pharmacologically isolated, evoked
NMDAR EPSCs with characteristic slow onset and offset (Fig.
7A). Unlike neurosteroid GABAergic PAMs (Harrison et al.,
1987) or AMPAR PAMs (Nagarajan et al., 2001), oxysterol analogues primarily augmented NMDAR EPSC peak amplitude,
rather than decay kinetics (Fig. 7C). On average 10 –90% decay
values were increased by 32 ⫾ 11% and 33 ⫾ 10% for 24(S)-HC
and SGE-201, respectively ( p ⫽ 0.02 and 0.06). By comparison,
neither AMPAR EPSCs nor GABAAR PSCs were significantly affected by 24(S)-HC or by SGE-201 (Fig. 7 B, D,E). Insensitivity of
GABAARs to 24(S)-HC is instructive because GABAARs are exquisitely sensitive to other neurosteroid-like molecules, including PREGS (Akk et al., 2001; Wang et al., 2002).
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robust LTP at 1 M (Fig. 8B). Similar to
results in cultured hippocampal neurons
(Fig. 2), SGE-201 was ⬃10-fold more potent than 24(S)-HC (Fig. 8).
In addition to enhancing LTP induction by weak tetanic stimulation in the
adult hippocampus, both 24(S)-HC and
SGE-201 reversed LTP deficits induced by
pretreatment with the NMDAR channel
blocker ketamine in hippocampal slices
from juvenile (P30) rats (Fig. 9). In these
experiments, pretreatment of slices with 1
M ketamine for 30 min results in LTP
inhibition that is observed subsequent to
ketamine washout and that persists for
⬎2 h. In the presence of 24(S)-HC or
SGE-201, tetanic stimulation produced
LTP that was sustained for over 1 h in
ketamine-pretreated slices. Similar results
were obtained with SGE-301 (data not
shown).
SGE-201 and SGE-301 reverse
behavioral deficits induced by NMDAR
channel blockers
Given the ability of SGE-201 and SGE-301
to enhance LTP induction in vitro, we determined whether systemic administration of these agents could reverse deficits
in rodent behavioral models. In contrast
Figure 10. SGE-201 and SGE-301 reverse behavioral deficits following NMDA receptor blockade. A, Pharmacokinetic profiles of to 24(S)-HC, systemic administration of
SGE-201(10 mg/kg, N ⫽ 3) and SGE-301(20 mg/kg, N ⫽ 2) following acute intraperitoneal administration in the mouse and rat SGE-201 or SGE-301 results in good sysrespectively. Inset, Brain concentrations measured at 60 min following compound administration. Note that SGE-301 treatment temic and brain concentrations (Fig.
resulted in a disproportionately higher brain concentration than SGE-201. B, SGE-201 reverses MK-801-nduced deficits in sponta- 10A). The brain concentration of SGEneous alternations in the Y-maze in mice (N ⫽ 17–19/group). Percentage alternation was significantly reduced by MK-801 301 is improved when compared with
compared with vehicle (#p ⬍ 0.0001). SGE-201 restores alternation after MK-801, with increased percentage alternation in the 3
SGE-201 (Fig. 10A, inset), as are its poand 10 mg/kg SGE-201 groups compared with MK-801 alone (***p ⬍ 0.0005 and *p ⬍ 0.05). C, SGE-301 rescues social interaction
tency
and intrinsic efficacy in potentiating
deficits in PCP-experienced rats (N ⫽ 12–15/group). Vehicle or PCP (5 mg/kg, bid, i.p.) was administered twice daily from days 1
NMDA
receptor function (e.g., Fig. 6B).
to 7. On day 14, SGE-301 was administered 60 min before testing. Time spent in active, nonaggressive social behavior was assessed
The ability of SGE-201 to reverse MKduring a 10 min session. PCP-experienced rats had significantly reduced interaction time compared with vehicle controls (#p ⬍
0.0001). SGE-301 (3 and 10 mg/kg, i.p.) restored social interaction in PCP-experienced rats with significantly increased interaction 801-induced impairment in spatial worktime (****p ⬍ 0.0001 and *p ⬍ 0.05) versus PCP ⫹ vehicle group. D, SGE-301 rescues novel object recognition in PCP- ing memory was assessed in a Y-maze
experienced rats (12–15/group). On day 21, 7 d after social interaction testing, rats were administered SGE-301 intraperitoneally spontaneous alternation task in mice. In
60 min before object training. After the 30 min retention interval, object recognition was assessed in a 3 min test session. this test, animals must recall which arms
Discrimination ratio (time spent exploring the novel object/time spent exploring both objects during the test session) was calcu- of the Y-maze they have previously exlated, so that a ratio of 0.5 corresponds to equal object preference (chance performance). Vehicle-treated PCP-experienced rats did plored in a trial, with an alternation connot exhibit novel object preference and had a significantly reduced discrimination ratio (#p ⬍ 0.0001) compared with vehiclesisting of successive entry into each of the
treated rats. SGE-301 (1 and 3 mg/kg) significantly increased the discrimination ratio in PCP-experienced (*p ⬍ 0.05 and **p ⬍
three arms of the maze without re-entry
0.01vs vehicle ⫹ PCP), demonstrating rescue of the object recognition deficit.
into a previously visited arm. Acute administration of the NMDAR channel
24(S)-Hydroxycholesterol and SGE-201 enhance
blocker, MK-801, significantly reduces the performance of anisynaptic plasticity
mals in this task, as measured by percentage of alternations durDo the potentiating effects of 24(S)-HC and SGE-201 on
ing a fixed testing interval. Treatment with SGE-201 produced a
NMDAR function at synapses influence synaptic plasticity? Consignificant reversal of MK-801-induced deficits at 3 and 10 mg/
sistent with evoked EPSC results in Figure 7, we found no effect of
kg, intraperitoneally ( p ⬍ 0.0005 and p ⬍ 0.05, respectively; Fig.
oxysterols on baseline AMPAR field fEPSPs from adult (P120) rat
10B). SGE-201 did not produce a significant effect on the overall
hippocampal slices. However, both SGE-201 and 24(S)-HC
number of arm entries in the Y-maze task ( p ⬎ 0.05).
transformed a normally subthreshold stimulus into a stimulus
In rats, subchronic (7 d) administration of the NMDAR chancapable of inducing LTP (Fig. 8 A, B). At P120, a single, highnel blocker, PCP (5 mg/kg, bid, i.p.) results in several behavioral
frequency tetanus produces only STP that fades to baseline
deficits that persist for up to 14 d following cessation of treatment
⬎15–20 min (Fig. 8). In the presence of 24(S)-HC or SGE-201,
(Grayson et al., 2007; Snigdha and Neill, 2008). In the current
the same single tetanus resulted in robust synaptic enhancement
study, at 7 d following cessation of PCP treatment, the duration
that persisted for over 1 h. The effects of 24(S)-HC were
of time spent in active social interaction was significantly ( p ⬍
concentration-dependent with marginal effects at 0.1 M and
0.001) reduced in PCP-experienced rats (32 ⫾ 3 s) compared
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with vehicle-treated rats (62 ⫾ 4 s; Fig. 10C). Acute administration of SGE-301 (3 and 10 mg/kg i.p.) significantly ( p ⬍ 0.001
and p ⬍ 0.05, respectively) increased time spent in active social
interactions in PCP-experienced rats (57 ⫾ 4 s and 48 ⫾ 3 s,
respectively) compared with vehicle-treated PCP-experienced
rats (32 ⫾ 3 s; Fig. 10C). Administration of risperidone (0.2 mg/
kg, i.p.) also significantly ( p ⬍ 0.05) increased time spent in
active social interactions (51 ⫾ 3 s) when compared with vehicletreated PCP-experienced rats (data not shown).
Subchronic administration of PCP also significantly impaired
performance in the NOR task when tested 14 d following cessation of PCP treatment (Fig. 10D). Due to their natural proclivity
for novelty, rodents normally spend more time exploring the
novel object in the test session, as demonstrated by the vehicletreated group. Novel object preference was eliminated in PCPexperienced rats, an effect that was significantly reversed by acute
administration of SGE-301 at 1 and 3 mg/kg intraperitoneally
( p ⬍ 0.05 and p ⬍ 0.01, respectively). Risperidone also improved
novel object preference in PCP-experienced rats ( p ⬍ 0.001, data
not shown). SGE-301 had no significant effect on locomotor activity in PCP-experienced rats during the NOR task ( p ⬎ 0.05).

Discussion
The synthesis of 24(S)-HC, the major cholesterol metabolite in
brain, is critical to brain cholesterol metabolism and turnover
(Lund et al., 2003; Russell et al., 2009). Unlike cholesterol,
24(S)-HC is membrane-permeable and readily enters the peripheral circulation, where it is subsequently metabolized and excreted (Lütjohann et al., 1996; Lund et al., 2003). 24(S)-HC has
been measured at very high concentrations in brain (10 –20 g/g
tissue or ⬃25 M) in a variety of mammalian species (Smith et al.,
1972; Meljon et al., 2012). Russell et al. (2009) have identified the
highly conserved cytochrome P450 enzyme (cholesterol 24hydroxylase, CYP46A1) responsible for synthesis of 24(S)-HC
from cholesterol (Lund et al., 1999). This enzyme is expressed
predominantly in the endoplasmic reticulum of neuronal cell
bodies and dendrites, but not axons (Ramirez et al., 2008). Importantly, cholesterol 24-hydroxylase deficiency disrupts hippocampal LTP and memory acquisition in mice (Kotti et al.,
2006) and this disruption of hippocampal LTP is rescued by geranylgeraniol diphosphate, a downstream nonsteroidal isoprenoid metabolite of mevalonate (Kotti et al., 2008). Our data
suggest that 24(S)-HC may also directly impact synaptic plasticity by modulating postsynaptic NMDARs in an autocrine manner near sites of 24(S)-HC synthesis (Ramirez et al., 2008).
Interestingly, the potency of 24(S)-HC at NMDARs is almost
10-fold greater than at LXRs, the other major target of 24(S)-HC
(Janowski et al., 1996; Kalaany and Mangelsdorf, 2006), and the
potency of 24(S)-HC at NMDARs in our study may represent an
underestimate given the slow onset time of oxysterol action.
Other potent LXR agonist oxysterols, such as 22(R)-HC and
20(S)-HC, are not active NMDAR modulators (Fig. 1B), and
neither SGE-201 nor SGE-301 are LXR agonists (data not
shown). Combined with the excised membrane patch data in
Figure 5, these observations indicate that LXRs do not mediate
the modulatory effects of 24(S)-HC on NMDARs.
Oxysterols are now well recognized as important signaling
molecules that interact with various soluble intracellular as well
as membrane-bound receptors. In addition to serving as ligands
for LXRs in a variety of tissues (Janowski et al., 1996; Kalaany and
Mangelsdorf, 2006), oxysterols bind with relatively high affinity
to membrane proteins including Insig proteins (Radhakrishnan
et al., 2007) and oxysterol-binding proteins (Banerji et al., 2010),

which act as oxysterol/cholesterol sensors to regulate cholesterol
synthesis and lipid metabolism. Oxysterols also activate the
Hedgehog (Hh) signaling pathway (Corcoran and Scott, 2006) by
binding to and allosterically activating the seven trans-membrane
protein Smoothened which mediates signal transduction by Hh
ligands (Nachtergaele et al., 2012). Thus, like steroids, oxysterols
can subserve cell signaling functions by binding to either soluble
or membrane-bound receptors and via both transcriptional and
post-translational mechanisms.
Our data on 24(S)-HC and NMDAR-mediated synaptic
transmission are reminiscent of previous work on neuroactive
steroids (Paul and Purdy, 1992), which directly enhance or inhibit synaptic transmission at GABA-ARs (Majewska et al., 1986;
Paul and Purdy, 1992) or NMDARs (Wu et al., 1991). PREGS,
one purported neurosteroid (Vallee et al., 1997), potentiates
NMDARs (Wu et al., 1991) and inhibits GABA-ARs (Akk et al.,
2001). Moreover, direct administration of PREGS to the CNS of
rodents has been reported to improve learning and memory and
to reverse the amnestic effects of NMDAR blockers (Flood et al.,
1992; Mathis et al., 1994). Nonetheless, PREGS seems unlikely to
play a significant role in the physiological regulation of NMDARs
as it is a relatively weak NMDAR PAM (EC50 ⱖ 50 M) (Wu et al.,
1991) and its presence in rodent brain is controversial (Liere et
al., 2009). Given its potency and high brain concentrations,
24(S)-HC is a more compelling candidate to modulate NMDARs
under physiological or pathophysiologic conditions. Further
work however will be required to determine whether 24(S)-HC
modulates NMDARs under physiological conditions. The availability of potent CYP46A1 inhibitors (Shafaati et al., 2010) and
CYP46A1-deficient mice (Lund et al., 2003) should facilitate
these studies. Nonetheless, regardless of a physiologic role for
24(S)-HC in regulating NMDAR function, it appears that the
novel oxysterol NMDAR modulatory site described here represents a potential target for drug discovery. The potencies of
24(S)-HC and its closely related synthetic analogs SGE-201
(Madau et al., 2009) and SGE-301 attest to the striking selectivity
of 24-hydroxylated oxysterols for NMDARs. Figure 1A shows
that these compounds bear significant structural similarity, particularly with respect to the 24-hydroxyl group of the sterol side
chain (at C-17) and the steroid backbone. The lack of any measurable activity of other endogenous oxysterols at NMDARs (Fig.
1B) as well as additional compounds synthesized in an attempt to
optimize the drug-like properties of this series (data not shown),
further supports the specificity of these 24(S)-hydroxylated oxysterols for NMDARs. Importantly, synthetic oxysterol derivatives, like SGE-201 and SGE-301, have desirable in vivo drug-like
properties, including excellent brain concentrations after parenteral dosing (Fig. 10A). The reversal of NMDAR blocker-induced
impairment of cognitive and social behavior following treatment
with SGE-201 or SGE-301 suggests that this novel oxysterol
NMDAR modulatory site could serve as a target for designing
drugs to treat a variety of neuropsychiatric disorders where augmenting NMDAR function may be of therapeutic benefit.
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J. Neurosci., October 30, 2013 • 33(44):17290 –17300 • 17299
hydroepiandrosterone in rodent brain: cholesterol autoxidation is the
key. J Lipid Res 50:2430 –2444. CrossRef Medline
Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959) Study of a
new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry
81:363–369. CrossRef Medline
Lund EG, Guileyardo JM, Russell DW (1999) cDNA cloning of cholesterol
24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc
Natl Acad Sci U S A 96:7238 –7243. CrossRef Medline
Lund EG, Xie C, Kotti T, Turley SD, Dietschy JM, Russell DW (2003)
Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brainspecific mechanism of cholesterol turnover. J Biol Chem 278:22980 –
22988. CrossRef Medline
Lütjohann D, Breuer O, Ahlborg G, Nennesmo I, Sidén A, Diczfalusy U,
Björkhem I (1996) Cholesterol homeostasis in human brain: evidence
for an age-dependent flux of 24S-hydroxycholesterol from the brain into
the circulation. Proc Natl Acad Sci U S A 93:9799 –9804. CrossRef
Medline
Madau P, Clark AG, Neale SA, Smith L, Hamilton N, Thomson F, Connick
JH, Belelli D, Lambert JJ (2009) Org 1, Org 2 and Org 3 potentiate
NMDA-receptor mediated responses in vitro. In: Program #613.2. Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2009.
Online.
Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM (1986) Steroid hormone metabolites are barbiturate-like modulators of the GABA
receptor. Science 232:1004 –1007. CrossRef Medline
Malayev A, Gibbs TT, Farb DH (2002) Inhibition of the NMDA response by
pregnenolone sulphate reveals subtype selective modulation of NMDA
receptors by sulphated steroids. Br J Pharmacol 135:901–909. CrossRef
Medline
Mathis C, Paul SM, Crawley JN (1994) The neurosteroid pregnenolone sulfate blocks NMDA antagonist-induced deficits in a passive avoidance
memory task. Psychopharmacology (Berl) 116:201–206. CrossRef
Medline
Meljon A, Theofilopoulos S, Shackleton CH, Watson GL, Javitt NB, Knölker
HJ, Saini R, Arenas E, Wang Y, Griffiths WJ (2012) Analysis of bioactive
oxysterols in newborn mouse brain by LC/MS. J Lipid Res 53:2469 –2483.
CrossRef Medline
Mennerick S, Que J, Benz A, Zorumski CF (1995) Passive and synaptic
properties of hippocampal neurons grown in microcultures and in mass
cultures. J Neurophysiol 73:320 –332. Medline
Mouriño A, Blair P, Wecksler W, Johnson RL, Norman AW, Okamura WH
(1978) Studies on vitamin D (calciferol) and its analogues: 15. 24-Nor1alpha,25-dihydroxyvitamin D3 and 24-nor-25-hydroxy-5,6-trans-vitamin
D3. J Med Chem 21:1025–1029. CrossRef Medline
Nachtergaele S, Mydock LK, Krishnan K, Rammohan J, Schlesinger PH,
Covey DF, Rohatgi R (2012) Oxysterols are allosteric activators of the
oncoprotein smoothened. Nat Chem Biol 8:211–220. CrossRef Medline
Nagarajan N, Quast C, Boxall AR, Shahid M, Rosenmund C (2001) Mechanism and impact of allosteric AMPA receptor modulation by the ampakine CX546. Neuropharmacology 41:650 – 663. CrossRef Medline
Ohtani Y, Irie T, Uekama K, Fukunaga K, Pitha J (1989) Differential effects
of alpha-, beta- and gamma-cyclodextrins on human erythrocytes. Eur
J Biochem 186:17–22. CrossRef Medline
Park-Chung M, Malayev A, Purdy RH, Gibbs TT, Farb DH (1999) Sulfated
and unsulfated steroids modulate ␥-aminobutyric acidA receptor function through distinct sites. Brain Res 830:72– 87. CrossRef Medline
Patneau DK, Mayer ML (1990) Structure-activity relationships for amino
acid transmitter candidates acting at N-methyl-D-aspartate and quisqualate receptors. J Neurosci 10:2385–2399. Medline
Paul SM, Purdy RH (1992) Neuroactive steroids. FASEB J 6:2311–2322.
Medline
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